SCHEMBL31246003

SCHEMBL31246003

CC(C)(O)c1ccc(Oc2cccc(OCCN3CCN(CCN4CCNCC4)CC3)c2)c(Br)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.48
▸ ALDH1A1 P00352 4/20 0.48
▸ GAA P10253 2/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ LMNA P02545 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ MAPT P10636 1/20 0.42
▸ CYP2D6 P10635 1/20 0.40
▸ PSMB1 P20618 1/20 0.40
▸ PSMB5 P28074 1/20 0.40
▸ PSMB2 P49721 1/20 0.40
▸ LTA4H P09960 2/20 0.39
▸ HRH3 Q9Y5N1 2/20 0.39
▸ EPHX2 P34913 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ DRD2 P14416 1/20 0.38
▸ DRD3 P35462 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32667893 0.77 BRD4 (0.51) —
SCHEMBL30812230 0.75 BRD4 (0.51) —
SCHEMBL13761603 0.73 KDM4E (0.57) KDM4EALDH1A1GAASMN1; SMN2LMNA
SCHEMBL11496309 0.72 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2LMNAMAPK1HTT
SCHEMBL8785521 0.71 ALDH1A1 (0.61) KDM4EALDH1A1SMN1; SMN2LMNAMAPK1
SCHEMBL5237958 0.71 KDM4E (0.64) KDM4EALDH1A1GAASMN1; SMN2LMNA
SCHEMBL32667700 0.70 EPHX2 (0.49) KDM4EALDH1A1GAALMNAEPHX2
SCHEMBL30812298 0.69 EPHX2 (0.50) KDM4EALDH1A1GAALMNAEPHX2
SCHEMBL11489219 0.69 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2LMNAHTTKMT2A
SCHEMBL13766381 0.69 KDM4E (0.63) KDM4EALDH1A1SMN1; SMN2LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4702022-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE Halda Therapeutics Opco, Inc. (US) 2026-03-04 — — EP disclosed
US-20260028338-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE HALDA THERAPEUTICS OPCO INC (US) 2026-01-29 — — US disclosed
WO-2024211684-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. (US) 2024-10-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028338-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, HCCS KDM4E 4246/4885ALDH1A1 211/4885GAA 3050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback